Belapectin is a Polysaccharide owned by Galectin Therapeutics, and is involved in 12 clinical trials, of which 9 were completed, 2 are ongoing, and 1 is planned.

Belapectin (GR-MD-02) acts by inhibiting galectin-3 proteins. The drug candidate targets galectin proteins which are key mediators of biologic and the pathologic function. The drug candidate has more affinity towards Galectin-3. By binding to the galectin-3 molecules, it prevents the galectin-3 from fostering harmful inflammation, excessive scar tissue build up and abnormal cellular growth. Disruption of the Galectin-3 gene blocks myofibroblast activation and is reversed by the addition of exogenous galectin-3.

The revenue for Belapectin is expected to reach a total of $2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Belapectin NPV Report.

Belapectin is originated and owned by Galectin Therapeutics.

Belapectin Overview

Belapectin (GR-MD-02) is under development for the treatment of NASH with advanced fibrosis, liver fibrosis and decompensated liver cirrhosis, kidney fibrosis, cardiovascular fibrosis, pulmonary arterial hypertension, arrhythmias, metastatic melanoma, lung fibrosis, prostate cancer, sarcomas, breast cancer, head and neck cancer squamous cell carcinoma, non-small cell lung cancer and portal hypertension. It is administered through intravenous route and targets galectin-3. It is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer that is comprised predominantly of galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. The drug candidate is developed based on the carbohydrate technology. It is a new chemical entity. It was also under development for the treatment of diabetic nephropathy, moderate to severe plaque psoriasis and severe atopic dermatitis.

Galectin Therapeutics Overview

Galectin Therapeutics is a biotechnology company. The company products includes for fibrosis, cancer immunotherapy, plaque psoriasis, and oral galectin-3 inhibitors. It discovers, develops and commercializes therapies for fibrotic disease and cancer. Galectin Therapeutics also offer products such as GR-MD-02, GM-CT-01. Its GR-MD-02 is a drug candidate used for treating fibrotic liver disease. Its GM-CT-01 is a vaccine used to treat patients with advanced melanoma, a deadly skin cancer. Galectin The company provides research, study of science of galectin proteins. Its products are used to treat fibrosis, galectin effects on liver fibrosis, lung fibrosis and cancer immunotherapy. Galectin Therapeutics is headquartered in Norcross, Georgia, the US.

The operating loss of the company was US$30.2 million in FY2021, compared to an operating loss of US$23.4 million in FY2020. The net loss of the company was US$30.5 million in FY2021, compared to a net loss of US$23.5 million in FY2020.

Quick View – Belapectin

Report Segments
  • Innovator
Drug Name
  • Belapectin
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Dermatology
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Immunology
  • Metabolic Disorders
  • Oncology
  • Respiratory
Key Companies
  • Sponsor Company: Galectin Therapeutics
  • Originator: Galectin Therapeutics
Highest Development Stage
  • Phase III


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.